Still Q4 and I still think it can get beyond .20. How far, I really don't know. A few if out catalysts are FDA related and less under control of AMBS in terms of timing. Lympro launch and/or sale and has the potential to really impact the share price. ODD designation for RP and IND submission for Eltoprazine are also huge. If Eltoprazine gets pushed to P3, watch out.